Our primary goal was to investigate whether treatment of CVVH-HP in patients with septic shock caused decreased vasoconstrictor and inotropic drug requirements. As a secondary objective, to determine whether CVVH-HP had an effect on inflammatory biomarkers and mortality. 11 septic shock patients who received CVVH-HP treatment within 12 months were included in the study. The following parameters were taken from patientsÂ medical records; hemodynamic parameters, infection markers, inotropes and vasopressors use. Also, Intensive care mortality and duration of ICU stay were assessed. The survival rate after the 24 hours from the start of treatment was 63.6% and 28 days survival rate was 36.4%. Four of the remaining seven survivors at the 24 hours were discharged home. CVVH- HP treatment was associated with an increase of mean arterial pressure, reduction of vasoconstrictor/ionotropic requirement, reduction of C-reactive protein and procalcitonin levels. In our retrospective study, we found that patients treated with CVVH-HP treatment had approximately 40% reduction in norepinephrine and dopamine requirement in the first 24 hours and patients had higher mean arterial pressures.